NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Intellia's securities between July 30, 2024, and January 8, 2025, during which they are encouraged to contact the Schall Law Firm before April 14, 2025 [2]. - The complaint alleges that Intellia provided false and misleading information regarding its drug development and marketing, leading to investor losses when the truth was revealed [4]. Group 2: Company Misconduct - Intellia reportedly gave investors a false impression of having reliable information about NTLA-3001, while its timelines and delivery methods were deemed unsustainable and inefficient [4]. - The company was unable to provide timely doses of NTLA-3001 or maintain adequate staffing, which contributed to the misleading nature of its public statements [4].